Philip Daffas, CEO of Painchek (ASX:PCK), spoke to us about his revolutionary Painchek pain monitoring tool, its utility in an aged care setting, how 2019 was a great year of growth in usage for Painchek and the company’s prospects for the 2020 as it heads towards filing for FDA approval.
